OSLO, Norway, Nov. 7, 2019 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage biotechnology company developing
immune activators to target hard-to-treat solid tumors, today
announces its third quarter 2019 results.
A meeting for investors, analysts and press will take place
in Oslo today at 10:00 CET (details below).
HIGHLIGHTS FOR THE THIRD QUARTER 2019
- Targovax announced data from part 1 of the ONCOS-102 trial in
checkpoint inhibitor refractory advanced melanoma, showing
validated clinical responses in three out of nine patients (33%
ORR), including one patient with a complete response and immune
activation in all nine patients
- The expansion part of the phase I/II trial of ONCOS-102 in
combination with the checkpoint inhibitor Imfinzi in patients with
advanced peritoneal malignancies opened for enrollment as the dose
escalation part of the trial concluded successfully
- Targovax announced the opening of Oslo
University Hospital as site for ONCOS-102 trial in
melanoma
POST-PERIOD HIGHLIGHTS
- In October, Targovax was selected for oral presentation at
Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting. The
presentation will be given bv Dr. Alexander
Shoushtari, Principal Investigator of ONCOS-102 trial in
melanoma, Memorial Sloan Kettering Cancer Center, NYC
Øystein Soug, CEO commented: "Oncolytic viruses are
increasingly recognized as an important future class of immune
activators, and Targovax is well positioned as one of the leaders
in this rapidly evolving field. Currently, our main focus is to
deliver the expected data read-outs from our ongoing ONCOS-102
combination trials in 2020, which we hope will solidify Targovax
position as a leader in the oncolytic virus space."
Presentation
The presentation will take place at 10:00
CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed
here.
Reporting material
Targovax 3Q presentation
Targovax 3Q report
The quarterly report and presentation are also available at the
website www.targovax.com.
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--third-quarter-2019-results,c2955744
The following files are available for download:
https://mb.cision.com/Public/17093/2955744/864b4fdbb5e5ac66.pdf
|
Targovax 3Q
presentation
|
https://mb.cision.com/Public/17093/2955744/90aeb95f8af1c777.pdf
|
Targovax 3Q
report
|
View original
content:http://www.prnewswire.com/news-releases/targovax-asa-third-quarter-2019-results-300953570.html
SOURCE Targovax